ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
  Madrid, Spain –21 October 2025. Today, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical...
3 min
21/10/2025
Laboratorios Farmacéuticos Rovi, S.A. announces that ROIS Phoenix Inc. (the “Buyer”), a wholly owned subsidiary of ROVI Pharma Industrial...
1 min
29/09/2025
​Operating revenue in the first half of 2025 was 314.6 million euros, a 4% decrease on the first half of 2024, mainly due to the...
3 min
24/07/2025